Literature DB >> 28174418

Liver cancer: Regorafenib as second-line therapy in hepatocellular carcinoma.

Austin G Duffy1, Tim F Greten1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28174418     DOI： 10.1038/nrgastro.2017.7

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  9 in total

1.  Under-representation of older adults in cancer registration trials: known problem, little progress.

Authors:  Kevin S Scher; Arti Hurria
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

2.  Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World.

Authors:  Sham Mailankody; Vinay Prasad
Journal:  JAMA Oncol       Date:  2017-07-01       Impact factor: 31.777

3.  Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis.

Authors:  Ghassan K Abou-Alfa; Dino Amadori; Armando Santoro; Arie Figer; Jacques De Greve; Chetan Lathia; Dimitris Voliotis; Sibyl Anderson; Marius Moscovici; Sergio Ricci
Journal:  Gastrointest Cancer Res       Date:  2011-03

4.  Microvessel density of hepatocellular carcinoma: its relationship with prognosis.

Authors:  H C Sun; Z Y Tang; X M Li; Y N Zhou; B R Sun; Z C Ma
Journal:  J Cancer Res Clin Oncol       Date:  1999-07       Impact factor: 4.553

5.  Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.

Authors:  Scott M Wilhelm; Jacques Dumas; Lila Adnane; Mark Lynch; Christopher A Carter; Gunnar Schütz; Karl-Heinz Thierauch; Dieter Zopf
Journal:  Int J Cancer       Date:  2011-04-22       Impact factor: 7.396

Review 6.  Advances in targeted therapies for hepatocellular carcinoma in the genomic era.

Authors:  Josep M Llovet; Augusto Villanueva; Anja Lachenmayer; Richard S Finn
Journal:  Nat Rev Clin Oncol       Date:  2015-06-09       Impact factor: 66.675

7.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Jordi Bruix; Shukui Qin; Philippe Merle; Alessandro Granito; Yi-Hsiang Huang; György Bodoky; Marc Pracht; Osamu Yokosuka; Olivier Rosmorduc; Valeriy Breder; René Gerolami; Gianluca Masi; Paul J Ross; Tianqiang Song; Jean-Pierre Bronowicki; Isabelle Ollivier-Hourmand; Masatoshi Kudo; Ann-Lii Cheng; Josep M Llovet; Richard S Finn; Marie-Aude LeBerre; Annette Baumhauer; Gerold Meinhardt; Guohong Han
Journal:  Lancet       Date:  2016-12-06       Impact factor: 79.321

8.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

9.  Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.

Authors:  Hanna K Sanoff; YunKyung Chang; Jennifer L Lund; Bert H O'Neil; Stacie B Dusetzina
Journal:  Oncologist       Date:  2016-05-16
  9 in total
  8 in total

1.  Real-Life Experience of Regorafenib in Patients With Advanced Hepatocellular Carcinoma.

Authors:  Jing-Yu Hou; Ya-Ting Xiao; Jing-Bo Huang; Xin-Hua Jiang; Kai Jiang; Xun Li; Li Xu; Min-Shan Chen
Journal:  Front Pharmacol       Date:  2022-06-06       Impact factor: 5.988

2.  The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma.

Authors:  David Agdashian; Mei ElGindi; Changqing Xie; Milan Sandhu; Drew Pratt; David E Kleiner; William D Figg; Julie A Rytlewski; Catherine Sanders; Erik C Yusko; Bradford Wood; David Venzon; Gagandeep Brar; Austin G Duffy; Tim F Greten; Firouzeh Korangy
Journal:  Cancer Immunol Immunother       Date:  2019-01-28       Impact factor: 6.968

3.  EIF3C-enhanced exosome secretion promotes angiogenesis and tumorigenesis of human hepatocellular carcinoma.

Authors:  Hsin-Yi Lee; Chi-Kuan Chen; Chun-Ming Ho; Szu-Shuo Lee; Chieh-Yu Chang; Kuan-Ju Chen; Yuh-Shan Jou
Journal:  Oncotarget       Date:  2018-01-11

Review 4.  Regulation of Src Family Kinases during Colorectal Cancer Development and Its Clinical Implications.

Authors:  Wook Jin
Journal:  Cancers (Basel)       Date:  2020-05-23       Impact factor: 6.639

5.  Regorafenib reverses HGF-induced sorafenib resistance by inhibiting epithelial-mesenchymal transition in hepatocellular carcinoma.

Authors:  Weibo Chen; Junsheng Yang; Yue Zhang; Huihua Cai; Xuemin Chen; Donglin Sun
Journal:  FEBS Open Bio       Date:  2019-01-18       Impact factor: 2.693

6.  Berberine Sensitizes Human Hepatoma Cells to Regorafenib via Modulating Expression of Circular RNAs.

Authors:  Kunyuan Wang; Ganxiang Yu; Jiaen Lin; Zhilei Wang; Qianting Lu; Chengxin Gu; Tao Yang; Shiming Liu; Hui Yang
Journal:  Front Pharmacol       Date:  2021-06-17       Impact factor: 5.810

7.  Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer.

Authors:  Zachary J Brown; Bernd Heinrich; Seth M Steinberg; Su Jong Yu; Tim F Greten
Journal:  J Immunother Cancer       Date:  2017-11-21       Impact factor: 13.751

Review 8.  The recent advancement of low-dimensional nanostructured materials for drug delivery and drug sensing application: A brief review.

Authors:  Hamidur Rahman; Md Rakib Hossain; Tahmina Ferdous
Journal:  J Mol Liq       Date:  2020-09-30       Impact factor: 6.165
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.